Featured Research

from universities, journals, and other organizations

L-DOPA therapy for Angelman syndrome may have both benefits and unanticipated effects, study suggests

Date:
November 12, 2012
Source:
University of North Carolina School of Medicine
Summary:
New research from the University of North Carolina provides a neurological justification for this therapeutic approach, but researchers caution there could be unanticipated effects.

In vivo voltammograms showing higher dopamine (DA) release in the nucleus accumbens (NAc) and lower release in the dorsal striatum of Angelman syndrome model mice (Ube3a m-/p+) compared to wild-type mice (WT).
Credit: Image courtesy of C.J. Malanga, MD, PhD

Last year a clinical trial of L-DOPA -- a mainstay of Parkinson's disease therapy -- was launched for Angelman syndrome, a rare intellectual disorder that shares similar motor symptoms such as tremors and difficulty with balance. The clinical trial is based on a 10-year-old case report showing benefit with the drug, but few studies since have explored the neurological justification for using L-DOPA to treat parkinsonian features in Angelman syndrome.

New research from the University of North Carolina School of Medicine, conducted in animal models of the disorder, now provides justification for this therapeutic approach. The study, published online ahead of print on Nov. 12 by the Journal of Clinical Investigation, suggests that L-DOPA could compensate for a loss of the neurochemical dopamine in the brain's motor pathways and improve motor symptoms. However, it also indicates that the drug could add to an already increased amount of dopamine in the brain's reward pathways and thus have unanticipated consequences on emotion and attention.

"The results were extremely surprising, because we don't know of any other disorder where dopamine is affected one way in one brain pathway and the opposite way in another," said Benjamin D. Philpot, PhD, associate professor of cell biology and physiology at UNC.

"If what we see in humans mirrors what we see in mice, then it does provide some optimism that L-DOPA might provide benefit for tremor," said C.J. Malanga, MD, PhD, associate professor of neurology at UNC. "But it also raises caution that researchers might want to consider assessing other aspects of Angelman syndrome that might be affected by dopamine -- not just motor symptoms but also other neuropsychiatric features." Malanga and Philpot are senior authors of the study.

Angelman syndrome affects about every one out of every 15,000 people. Individuals with the disorder have minimal verbal communication -- some never speak a single word -- as well as seizures and motor problems. It is caused by defects in UBE3A, a gene involved in the development of the brain's wiring. Much of what has been learned about this gene has come from a mouse model lacking UBE3A.

Philpot and Malanga decided to use these Angelman syndrome model mice to explore how dopamine is affected in Angelman syndrome. Dopamine is a well-known neurotransmitter, one of many chemicals responsible for transmitting signals between neurons in the brain. In their experiments, the researchers found that the behavioral deficits seen in the Angelman syndrome model were not due to the loss of dopamine-producing brain cells -- as in Parkinson's disease -- or reduced production of the important neurochemical.

Rather, they found that it was associated with differences in release of the dopamine molecule from brain cells. Specifically, dopamine release was decreased in one brain pathway -- the motor or nigrostriatal pathway -- and increased in another -- the reward or mesolimbic pathway. But instead of having a greater effect on reward, dopamine also appeared to be less effective at motivating behavior in these mice.

"One of the interesting features of people with Angelman syndrome is that they generally have a very happy disposition and a lower threshold for humor. It is interesting that we found this effect in the reward pathway, because it could provide a biological basis for this happy disposition," said Philpot.

Malanga cautions that this happy disposition, as well as the lack of communication skills, might make it hard for researchers to tell if their Angelman syndrome patients are experiencing negative consequences of an altered reward pathway, such as changes in mood or compulsive behaviors. Therefore, he recommends that clinical trials assess many different outcome measures to ensure that L-DOPA treatment does not lead to unanticipated outcomes.

The research was funded by the National Institutes of Health, the Simons Foundation, the Angelman Syndrome Foundation and Autism Speaks. Study co-authors from UNC were Thorfinn T. Riday; Elyse C. Dankoski; Michael C. Krouse; Eric W. Fish, PhD; Paul L. Walsh; Ji Eun Han; Clyde W. Hodge, PhD; and R. Mark Wightman, PhD.


Story Source:

The above story is based on materials provided by University of North Carolina School of Medicine. Note: Materials may be edited for content and length.


Journal Reference:

  1. Thorfinn T. Riday, Elyse C. Dankoski, Michael C. Krouse, Eric W. Fish, Paul L. Walsh, Ji Eun Han, Clyde W. Hodge, R. Mark Wightman, Benjamin D. Philpot, C.J. Malanga. Pathway-specific dopaminergic deficits in a mouse model of Angelman syndrome. Journal of Clinical Investigation, 2012; DOI: 10.1172/JCI61888

Cite This Page:

University of North Carolina School of Medicine. "L-DOPA therapy for Angelman syndrome may have both benefits and unanticipated effects, study suggests." ScienceDaily. ScienceDaily, 12 November 2012. <www.sciencedaily.com/releases/2012/11/121112171223.htm>.
University of North Carolina School of Medicine. (2012, November 12). L-DOPA therapy for Angelman syndrome may have both benefits and unanticipated effects, study suggests. ScienceDaily. Retrieved July 28, 2014 from www.sciencedaily.com/releases/2012/11/121112171223.htm
University of North Carolina School of Medicine. "L-DOPA therapy for Angelman syndrome may have both benefits and unanticipated effects, study suggests." ScienceDaily. www.sciencedaily.com/releases/2012/11/121112171223.htm (accessed July 28, 2014).

Share This




More Health & Medicine News

Monday, July 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

$15B Deal on Vets' Health Care Reached

$15B Deal on Vets' Health Care Reached

AP (July 28, 2014) A bipartisan deal to improve veterans health care would authorize at least $15 billion in emergency spending to fix a veterans program scandalized by long patient wait times and falsified records. (July 28) Video provided by AP
Powered by NewsLook.com
Traditional African Dishes Teach Healthy Eating

Traditional African Dishes Teach Healthy Eating

AP (July 28, 2014) Classes are being offered nationwide to encourage African Americans to learn about cooking fresh foods based on traditional African cuisine. The program is trying to combat obesity, heart disease and other ailments often linked to diet. (July 28) Video provided by AP
Powered by NewsLook.com
West Africa Gripped by Deadly Ebola Outbreak

West Africa Gripped by Deadly Ebola Outbreak

AFP (July 28, 2014) The worst-ever outbreak of the deadly Ebola epidemic grips west Africa, killing hundreds. Duration: 00:48 Video provided by AFP
Powered by NewsLook.com
Trees Could Save More Than 850 Lives Each Year

Trees Could Save More Than 850 Lives Each Year

Newsy (July 27, 2014) A national study conducted by the USDA Forest Service found that trees collectively save more than 850 lives on an annual basis. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins